世界卫生组织(WHO)2021年胶质瘤、胶质神经元和神经元肿瘤分类的分子诊断工具:EANO指南
该指南由EANO制定,针对WHO 2021中枢神经系统肿瘤分类(CNS5)中胶质瘤、胶质神经元和神经元肿瘤的分子诊断方法,系统讨论了DNA和RNA二代测序、甲基化谱分析、单/有限靶点检测(含免疫组化)及MGMT启动子甲基化分析等方法,并给出基于证据等级的推荐。
要点
- WHO 2021分类中多种分子特征成为诊断标准,需整合组织分子诊断。
- 指南覆盖DNA/RNA二代测序、甲基化谱分析、单靶点检测及免疫组化。
- 因MGMT启动子甲基化在IDH野生型胶质母细胞瘤中的预测价值,指南涵盖其分析工具。
核心结论
- 指南系统讨论了用于胶质瘤、胶质神经元和神经元肿瘤诊断的最具信息量的诊断和预后分子标志物检测方法,并提供了推荐和可获得的证据等级信息。
研究设计与样本
- EANO指南,针对WHO 2021中枢神经系统肿瘤分类(CNS5)中胶质瘤、胶质神经元和神经元肿瘤的分子诊断方法。
主要发现
- WHO 2021分类中多种分子特征成为许多额外CNS肿瘤类型的必要诊断标准,这些肿瘤需要整合的「组织分子」诊断。
- 指南覆盖DNA和RNA二代测序、甲基化谱分析以及包括免疫组化在内的单/有限靶点分析精选检测。
- 指南涵盖MGMT启动子甲基化状态分析工具,因为其在IDH野生型胶质母细胞瘤中作为预测标志物的重要性。
- 指南提供了不同检测方法特性(尤其是优势和局限性)的结构化概述,并阐明了对输入材料和结果报告的要求。
- 指南还讨论了分子诊断检测在临床相关性、可及性、成本、实施、监管和伦理方面的通用问题,并展望了神经肿瘤学分子检测技术领域的新发展。
关键数值与推荐
- WHO 2021分类(CNS5)中,多种分子特征成为许多额外CNS肿瘤类型的必要诊断标准,这些肿瘤需要整合的「组织分子」诊断。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the 5th edition of the WHO CNS tumor classification (CNS5, 2021), multiple molecular characteristics became essential diagnostic criteria for many additional CNS tumor types. For those tumors, an integrated, "histomolecular" diagnosis is required. A variety of approaches exists for determining the status of the underlying molecular markers. The present guideline focuses on the methods that can be used for assessment of the currently most informative diagnostic and prognostic molecular markers for the diagnosis of gliomas, glioneuronal and neuronal tumors. The main characteristics of the molecular methods are systematically discussed, followed by recommendations and information on available evidence levels for diagnostic measures. The recommendations cover DNA and RNA next-generation-sequencing, methylome profiling, and select assays for single/limited target analyses, including immunohistochemistry. Additionally, because of its importance as a predictive marker in IDH-wildtype glioblastomas, tools for the analysis of MGMT promoter methylation status are covered. A structured overview of the different assays with their characteristics, especially their advantages and limitations, is provided, and requirements for input material and reporting of results are clarified. General aspects of molecular diagnostic testing regarding clinical relevance, accessibility, cost, implementation, regulatory, and ethical aspects are discussed as well. Finally, we provide an outlook on new developments in the landscape of molecular testing technologies in neuro-oncology.
引用
- Sahm F, Brandner S, Bertero L, et al. Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline. Neuro Oncol. 2023. PMID: 37279174. doi:10.1093/neuonc/noad100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。